HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study.

AuthorsKaroline Krause, Aos Mahamed, Karsten Weller, Martin Metz, Torsten Zuberbier, Marcus Maurer
JournalThe Journal of allergy and clinical immunology (J Allergy Clin Immunol) Vol. 132 Issue 3 Pg. 751-754.e5 (Sep 2013) ISSN: 1097-6825 [Electronic] United States
PMID23711544 (Publication Type: Controlled Clinical Trial, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin 1 Receptor Antagonist Protein
  • Interleukin-1beta
  • Interleukin-6
  • canakinumab
  • C-Reactive Protein
Topics
  • Anti-Inflammatory Agents (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Blood Sedimentation
  • C-Reactive Protein (analysis)
  • Humans
  • Interleukin 1 Receptor Antagonist Protein (blood)
  • Interleukin-1beta (antagonists & inhibitors)
  • Interleukin-6 (blood)
  • Pilot Projects
  • Treatment Outcome
  • Urticaria (blood, drug therapy)
  • Vasculitis, Leukocytoclastic, Cutaneous (blood, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: